B7-H3 of the B7 family is highly expressed in over 70% of GBM specimens [23], and B7-H3-targeting immunotherapies are currently under clinical investigation in children and adults with refractory extracranial solid tumors and brain tumors (NCT02982941, NCT01391143, and NCT04185038) [24–26]. This evidence concerns the gene CD276 and brain neoplasm.